amitriptyline / Generic mfg. - LARVOL DELTA

Sedative co-medication patterns across frailty states in people with HIV: a network-based study. (PubMed, Int J Clin Pharm) - "Sedative co-medication patterns vary meaningfully across frailty states in people with HIV. Frailty is associated with more complex networks and a greater likelihood of high-risk drug interactions. Medications influencing these patterns can help identify opportunities for safer prescribing. The prefrail stage may offer a timely window for interventions aimed at minimizing polypharmacy and improving safety in middle-aged and older adults with HIV."

Journal • Human Immunodeficiency Virus • Infectious Disease

MULTIMODAL ANALGESIA for Refractory NEUROPATHIC PAIN in End-Stage SÉZARY SYNDROME: A case report. (ASA 2025) - "The anesthesiology painteam implemented a multimodal regimen consisting of amitriptyline, gabapentin,oral morphine, and dipyrone. No adverse effects were observed. Pain remained well-controlled until the patient'speaceful death, without the need for sedation or cardiopulmonary resuscitation.This case highlights the pivotal role of the anesthesiology pain team in oncologic care and demonstrates the effectiveness of early multimodal analgesia in restoring comfort and dignity to terminal patients."

Case report • Clinical • Anesthesia • Cutaneous T-cell Lymphoma • Neuralgia • Pain • Sezary Syndrome

Amitriptyline inhibits Plasmodium development in infected red blood cells by modulating sphingolipid metabolism and glucose uptake. (PubMed, Biomed Pharmacother) - "Mechanistically, we elucidate that amitriptyline impedes intra-erythrocytic parasite development, due to a reduced glucose uptake and thereby interfering with the spreading of blood-stage Plasmodium parasites. Our findings highlight the therapeutic promise of targeting sphingolipid metabolism to combat Plasmodium infections."

Journal • Infectious Disease • Malaria • Metabolic Disorders

Neurogenic Cough: A Systematic Review of Etiologies and Treatment Modalities (AAO-HNSF 2025) - "Gabapentin and pregabalin demonstrated the highest efficacy, achieving symptom reduction in 68% of patients, while speech therapy improved cough severity scores by 40%. Python-based NLP revealed a rising focus on neuromodulators (e.g., amitriptyline) and non-invasive vagal nerve stimulation as novel therapies... Neurogenic cough management benefits from neuromodulators and targeted speech therapy, though standardized diagnostic criteria are urgently needed. The integration of R and Python enabled robust data synthesis and identified gaps in mechanistic understanding. Future research should prioritize randomized controlled trials to validate emerging therapies and refine etiology-driven treatment algorithms."

Review • Chronic Cough • Cough • Pain • Respiratory Diseases

A Refractory, Gas-Predominant Subgroup of Irritable Bowel Syndrome Markedly Improved With Relatively Long-Term Paroxetine Treatment: A Preliminary Study. (PubMed, Cureus) - "Patients with gas-predominant IBS were treated with paroxetine, amitriptyline, or both. Paroxetine treatment for a relatively long period may be effective in treating refractory gas-predominant IBS. However, this study was open-label and lacked a control group, and future investigations are needed to determine the most appropriate use of paroxetine for the treatment of gas-predominant IBS."

Journal • CNS Disorders • Depression • Gastroenterology • Gastrointestinal Disorder • Major Depressive Disorder • Mental Retardation • Mood Disorders • Psychiatry

Effect of Amitriptyline and Trifluoperazine on Patients With Functional Dyspepsia (clinicaltrials.gov) - P2/3 | N=150 | Recruiting | Sponsor: Md. Moktadirul Hoque Shuvo | Not yet recruiting ➔ Recruiting

Enrollment open • Dyspepsia

Machine learning-based model for behavioural analysis in rodents applied to the forced swim test. (PubMed, Sci Rep) - "Our ML model was validated against manual scoring in rats treated with fluoxetine and desipramine, two antidepressants known to induce distinct behavioural patterns...Subsequently, we successfully validated our model by testing its ability to distinguish between drugs that predominantly evoke climbing (i.e., amitriptyline), those that preferentially facilitate swimming (i.e., paroxetine), and those that evoke both in a more balanced manner (i.e., venlafaxine). This approach represents a significant advancement in preclinical research, providing a more accurate and efficient method to analyze forced swimming data in rodents. We anticipate that in addition to the FST, our model and approach could be extended for application to various behavioural tests in laboratory animals, by training with specific datasets."

Journal • Preclinical

Prevalence and predictors of non-medical and lifetime use of controlled drugs among patients accessing mental health services at the university of Gondar comprehensive specialized hospital: Northwest Ethiopia. (PubMed, BMC Psychiatry) - "The results of this study revealed that tramadol, in both intravenous and oral forms, was the most frequently abused drug. It was found that patients treated in outpatient settings had greater exposure to CPD use. It is crucial to evaluate the impact of nonmedical CPD use on the health of individuals with mental health conditions and prioritize efforts to improve the quality of care for high-risk individuals."

Journal • Pain

Investigation of potential toxicity associated with long-term amitriptyline exposure: Evidence from genomics. (PubMed, Ecotoxicol Environ Saf) - "Finally, molecular docking simulations (AutoDock Vina v1.2.7, AlphaFold structures) provided structural evidence for AT interactions with key targets including TRPV1. Collectively, these findings suggest that pharmacological inhibition or environmental accumulation of AT may contribute to inflammatory skin reactions and pancreatic tumorigenesis through multiple converging molecular pathways."

Adverse events • Journal • Dermatology • Immunology • Inflammatory Arthritis • Lupus • Oncology • Pancreatic Cancer • Psoriasis • Rosacea • Solid Tumor • Systemic Lupus Erythematosus • SLC6A4 • TRPV1

Treatment Preferences in Patients With Insomnia and Medical Comorbidity: Associated Factors and Impact on Treatment-Outcome. (PubMed, J Sleep Res) - "This study aimed to (1) identify factors influencing treatment preference in these patients, and (2) assess how aligning treatment with patient preferences impacts outcomes for CBT-I and low-dose Amitriptyline...Our findings suggest that when treatment does not align with a patient's preference, CBT-I results in a better treatment-outcome than medication. Trial Registration: Dutch Trial Register: NTR NL7971."

Journal • CNS Disorders • Insomnia • Sleep Disorder

Repurposing Tricyclic Antidepressants for Glioblastoma Treatment (EACR 2025) - "Our lab has previously proposed a successful novel combinatorial regimen, including the tricyclic antidepressant (TCA) imipramine, the vascular endothelial growth factor (VEGF) inhibitor bevacizumab, and the immune checkpoint inhibitor anti-PD-L1, which demonstrated significant therapeutic benefit in GBM mouse models (Chryplewicz et al.; Cancer Cell, 2022)...Motivated by these results and encouraged by the clinical support, we aim to further improve this therapeutic regimen by disrupting various capabilities of tumors required for their growth and therapeutic resistance.Material and To optimize this regimen for clinical translation, we screened multiple TCAs - trimipramine, clomipramine, and amitriptyline - alongside imipramine in mouse and human GBM cell lines to evaluate their impact on cell viability... This study aims to delve deeper into TCA mechanisms of action, assess potential synergies with VEGF pathway inhibitors and immune checkpoint blockade, and ultimately..."

IO biomarker • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

Bladder pain syndrome (PubMed, Rev Prat) - "The first line of treatment usually includes cystoscopy with hydrodistension in the case of parietal forms, introduction of amitriptyline, physiotherapy, diet and TENS (Transcutaneous Electrical Nerve Stimulation). A better understanding of the underlying mechanisms would enable us to propose an even more individualized treatment, specific to the BPS phenotype."

Journal • Anesthesia • Bladder Cancer • Gynecology • Infectious Disease • Interstitial Cystitis • Musculoskeletal Pain • Oncology • Pain • Solid Tumor

Identifying Predictors of Serious Adverse Events in Antidepressant Treatment from a Decade-Long Nationwide Pharmacovigilance Study: Impact of Dementia and Parkinson's Disease Treatment. (PubMed, Medicina (Kaunas)) - " Among 21,103 antidepressant-related ADEs, duloxetine was the most etiologic medication, followed by amitriptyline and escitalopram. Fluoxetine is the only agent with a high likelihood of reporting SAEs... The type of antidepressant, concomitant medications, and sex are major predictors for SAE risk. Further controlled studies on the impact of comorbidities and polypharmacy on antidepressant-related SAEs are warranted."

Adverse events • Journal • Serious adverse event • Alzheimer's Disease • CNS Disorders • Dementia • Depression • Movement Disorders • Parkinson's Disease • Psychiatry

Headphone headache (AHS 2025) - "She noted that her migraines worsened with the development of scalp allodynia where she became refractory to several pharmaceutical treatments including propranolol, cyproheptadine, amitriptyline, nortriptyline, topiramate, zonisamide, venlafaxine, erenumab, galcanezumab, and magnesium infusions. One case is described in which pain associated with external compression headache in the setting of prolonged headphone use was decreased by onabotulinum toxin injections. We hypothesize that, similar in the treatment of migraine, onabotulinum toxin may work to dampen the central sensitization of the sensory neurons associated with allodynia. More research is necessary to confirm our findings."

CNS Disorders • Depression • Migraine • Musculoskeletal Pain • Pain • Psychiatry

An interdisciplinary approach to medication overuse headache: A case study (AHS 2025) - "She had tried and failed Botulinum toxin injections, occipital nerve blocks and trigger point injections, sphenopalatine ganglion blocks, Amitriptyline, Propranolol, Venlafaxine, Emgality, Aimovig, Vyepti, Qulipta, and Cefaly. The interdisciplinary model with headache neurology, occupational therapy, pain psychology, and physical therapy allowed for continued reinforcement and collaborative integration to allow for a more in-depth assessment of the barriers contributing to medication overuse headache and the implementation of a successful, sustainable plan. The patient was successfully able to stop Excedrin and reduce Sumatriptan use significantly, implement self-regulation and cognitive strategies for pain and anxiety management, and reduce her monthly headache and migraine days by more than 75%. Emotion wheel"

Case study • Clinical • CNS Disorders • Cognitive Disorders • Depression • Migraine • Mood Disorders • Musculoskeletal Pain • Neuralgia • Pain • Psychiatry

Low dose amitriptyline versus cognitive behavioral therapy for insomnia in patients with medical comorbidity: results of a randomized controlled multicenter non inferiority trial. (PubMed, Sleep) - "With a liberal non-inferiority margin, AM is non-inferior to CBT-I in reducing insomnia severity. AM has more side effects and its effect on insomnia may diminish after tapering. CBT-I should remain first-line treatment for patients with medical comorbidity given its broader benefits."

Head-to-Head • Journal • CNS Disorders • Insomnia • Sleep Disorder

Effectiveness of amitriptyline, duloxetine and pregabalin in pudendal neuralgia management: a comparative study (NeuPSIG 2025) - No abstract available

CNS Disorders • Neuralgia • Pain

Comparative Toxicokinetics and Biomarker Responses of Typical Psychiatric Pharmaceuticals in Daphnia magna. (PubMed, Toxics) - "In this study, eight typical PDs [carbamazepine (CBZ), citalopram (CIT), sertraline (SER), venlafaxine (VLF), amitriptyline (AMT), chlorpromazine (CPM), quetiapine (QTP) and clozapine (CLZ)] were selected to study the uptake, depuration and biological effects of PDs in Daphnia magna. The Ku of PDs, oxidative stress and metabolic level of D. magna combine to affect BCF levels together. In conclusion, this study contributes to a better understanding of the toxicokinetics and biochemical responses of PDs in D. magna and potential mechanisms of action, which may allow for a better assessment of their environmental health risks to aquatic ecosystems."

Biomarker • Journal • Pain • Psychiatry

Impact of Antidepressants on Dental Implant Osseointegration: A Comparative Evaluation of Nanohydroxyapatite and Double Acid-Etching Surface Treatments. (PubMed, Int J Oral Maxillofac Implants) - "It can be concluded that the antidepressants studied were associated with a higher possibility of osseointegration failure. Implants featuring NANO surface treatment could be used as an alternative in these instances to mitigate the negative impact of antidepressant therapy on bone repair."

Journal • CNS Disorders • Depression • Psychiatry

A Comparative Systematic Review and Meta-analysis of Amitriptyline with Propranolol and Flunarizine for the Prophylaxis of Migraine Headache. (PubMed, J Assoc Physicians India) - "Low-dose amitriptyline is a potent prophylactic treatment option for migraine with respect to frequency, duration, as well as severity of migraine episodes. Its efficacy profile is superior to placebo as well as propranolol and comparable to flunarizine, whereas safety profile is comparable to both propranolol and flunarizine."

Clinical • Journal • Retrospective data • Review • CNS Disorders • Migraine • Pain

Tricyclic antidepressants dose-dependently modulate the biphasic activity of the TRPC5 channel through opioid receptors. (PubMed, Korean J Physiol Pharmacol) - "Without altering TRPC5 expression levels, TCAs (amitriptyline, desipramine, and imipramine) dose-dependently reduced inward currents through TRPC5, with IC₅₀ values of 2.9, 10.3, and 11.7 μM, respectively. The biphasic modulation of TRPC5 by TCAs may contribute to a wide spectrum of cardiovascular and neurological manifestations, depending on the dosage and clinical application. Overall, these findings enhance the pharmacological understanding of the molecular mechanisms underlying the actions of TCAs and emphasize the need for more targeted therapeutic approaches."

Journal • Addiction (Opioid and Alcohol) • Cardiovascular • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry • TRPC5

JB Chemicals gets US FDA approval for depression medication (CNBC-TV18) - "J B Chemicals and Pharmaceuticals Ltd has received final approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for Amitriptyline Hydrochloride Tablets USP. The approved dosages—10 mg, 25 mg, 50 mg, 75 mg, 100 mg and 150 mg—are indicated for the relief of symptoms of depression. Amitriptyline Hydrochloride is a tricyclic antidepressant commonly prescribed to manage major depressive disorders."

ANDA • Depression

Case report and systematic review of literature on adolescent trigeminal neuralgia (AHS 2025) - "She was treated with topiramate, gabapentin, amitriptyline, duloxetine, acetazolamide, baclofen, and phenytoin, all with minor pain relief, however significant cognitive side effects which resulted in difficulty at school...She continued on carbamazepine and gabapentin, despite the cognitive side effects causing difficulty in college... There is limited awareness and lifestyle treatment considerations to consider in adolescent trigeminal neuralgia. It is likely that having a multidisciplinary care model is best in pediatric trigeminal neuralgia, to include pediatric neurology, adult neurology, neurosurgery, dentistry, and psychology. Additionally, pediatric neurologists will be less familiar with this diagnosis and adult neurologists may not be comfortable treating this population or be aware of the various intricacies in the care."

Case report • Clinical • Review • CNS Disorders • Epilepsy • Migraine • Neuralgia • Pain • Psychiatry

Case report: Atypical onset and recovery of Raynaud's phenomenon with galcanezumab with concurrent rizatriptan (AHS 2025) - "Galcanzeumab was discontinued and amitriptyline was started as preventative. Through initiation and discontinuation of galcanzeumab, the patient used rizatriptan as their abortive agent. It has been documented that triptans can also cause RP. The concurrent use of galcanzeumab and rizatriptan may have expedited the presentation of RP but did not affect recovery after discontinuation of only galcanzeumab."

Case report • Clinical • CNS Disorders • Depression • Migraine • Pain • Psychiatry

Effectiveness of treatments used in new daily persistent headache in children & adolescents (AHS 2025) - "First prescription preventive, usually amitriptyline or topiramate, offered similar benefit (37/106, 35%) as first supplement, but with more negative outcomes (25/106, 24%). Despite being tried after oral preventives, onabotulinumtoxinA injections offered benefit to the largest proportion (14/20, 70%) without negative outcomes (0%)... Youth with NDPH experience treatment delays which may hamper benefit. Clinicians should consider use of bridge therapies in combination with preventive treatments as early as possible. Non-medication therapy, such as CBT, should also be initiated as early as possible."

Clinical • CNS Disorders • Migraine • Pain